Results 61 to 70 of about 49,535 (243)

Case Series of Sustained Fluid-Associated Weight Gain Following Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy. [PDF]

Pediatr Pulmonol
Pediatric Pulmonology, Volume 61, Issue 9, September 2026.
Tillman EM, Lazutina A, Robinson RC, Colwell A, Brown CD.   +4 more
europepmc   +2 more sources

Impact of Highly Effective Modulator Therapy on Olfactory‐Specific Gene Expression in People With Cystic Fibrosis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis is common in people with cystic fibrosis (PwCF). Highly effective modulator therapy (HEMT) has been shown to improve sinonasal outcomes. However, prior studies failed to show improvement in objective olfaction with HEMT, and the impact of HEMT on olfactory‐specific quality of life has yet to be studied ...
Michael R. Xiang, Ankit Chauhan, Gina Hong, Denis Hadjiliadis, Daniel Dorgan, Michael M. Rey, Samantha Kane, James N. Palmer, Nithin D. Adappa, Noam A. Cohen, Michael A. Kohanski, Jennifer E. Douglas   +11 more
wiley   +1 more source

Cystic Fibrosis Polymorphic Variants in a Russian Population

Pharmacogenomics and Personalized Medicine, 2020
Anna Kiseleva,1,* Marina Klimushina,1,* Evgeniia Sotnikova,1,* Olga Skirko,1 Mikhail Divashuk,1,2 Olga Kurilova,1 Alexandra Ershova,1 Eleonora Khlebus,1 Anastasia Zharikova,1,3,4 Irina Efimova,1 Maria Pokrovskaya,1 Petr A Slominsky,5 Svetlana Shalnova,1 ...
Kiseleva A, Klimushina M, Sotnikova E, Skirko O, Divashuk M, Kurilova O, Ershova A, Khlebus E, Zharikova A, Efimova I, Pokrovskaya M, Slominsky PA, Shalnova S, Meshkov A, Drapkina O   +14 more
doaj  

CFTR Genotype and Maximal Exercise Capacity in Cystic Fibrosis: A Cross-sectional Study.

, 2017
RATIONALE Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human skeletal muscle cells. Variations of CFTR dysfunction among patients with CF may present an important determinant of aerobic exercise capacity in CF.
Helge Hebestreit, Lands, Larry C, Mei-Zahav, Meir, Hatziagorou, Elpis, Urquhart, Don S, Jakob Usemann, Hulzebos, Erik Hj, Gallati, Sabina, Tejero, Sergio, Elpis Hatziagorou, Meir Mei-Zahav, Tim Takken, Braun, Julia, Aleksandar Sovtic, CFTR-Exercise Study Group, Kriemler, Susi, Karila, Chantal, Sovtic, Aleksandar, Usemann, Jakob, Felix Ratjen, Daniel Stevens, Milos Petrovic, Petrovic, Milos, Thomas Radtke, Daniela Savi, Tiffany Dwyer, Stevens, Daniel, Savi, Daniela, Sabina Gallati, Ryan A. Harris, Schneiderman, Jane E, Chantal Karila, Hebestreit, Helge, Steven R. Boas, Takken, Tim, Jane E. Schneiderman, Boas, Steven R, Ratjen, Felix, Sergio Tejero, Susi Kriemler, Dwyer, Tiffany, Larry C. Lands, Radtke, Thomas, Julia Braun, Harris, Ryan A, Don S. Urquhart, Erik H. J. Hulzebos   +46 more
core   +1 more source

Olfactory Function in Cystic Fibrosis: Outcome Measures, Olfactory Dysfunction Prevalence and the Impact of Management—A Systematic Review and Meta‐Analysis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Olfactory dysfunction (OD) is an increasingly recognized but under‐investigated comorbidity of cystic fibrosis (CF). Its prevalence, assessment methods, and response to CF‐directed treatment, including highly effective modulator therapy (HEMT) remains incompletely characterized.
Luca Cox, Kofi Cox, Katherine Whitcroft, Susanne Weise, Sonal Kansra, Eishaan Bhargava   +5 more
wiley   +1 more source

DIAGNOSTIC PROBLEMS OF MUCOVISCIDOSIS AND WAYS OF SOLUTION IN RUSSIA

Педиатрическая фармакология, 2014
Mucoviscidosis is a monogenic autosomal recessive caused by the CFTR gene mutations and characterized by pronounced genetic heterogeneity and clinical polymorphism, which emphasizes the need in comprehensive diagnosis and molecular-genetic verification ...
A. A. Baranov, N. I. Kapranov, N. Yu. Kashirskaya, L. S. Namazova-Baranova, V. D. Sherman, O. I. Simonova, A. Yu. Tomilova, K. V. Sevost'yanov, A. M. Pushkov, A. L. Vladykin, N. V. Shatokhin   +10 more
doaj   +1 more source

Image1_Pharmacological Responses of the G542X-CFTR to CFTR Modulators.tiff

, 2022
Cystic fibrosis (CF) is a lethal hereditary disease caused by loss-of-function mutations of the chloride channel cystic fibrosis transmembrane conductance regulator (CFTR). With the development of small-molecule CFTR modulators, including correctors that
Jiunn-Tyng Yeh (6166379), Xinxiu Fang (1304898), Tzyh-Chang Hwang (1578925)   +2 more
core   +1 more source

Engineering Biology Beyond Single Genes: Advances and Challenges in Multiplex Genome Editing

Animal Research and One Health, EarlyView.
Multiplex genome editing is transforming genome engineering from single‐gene perturbation to network‐level control, yet its broader application remains limited by challenges in gRNA array engineering, delivery technologies, and safety management. Emerging AI‐driven approaches are accelerating guide RNA design and CRISPR effector optimization for ...
Linli Wang, Yongbin Liu, Hongbing Han
wiley   +1 more source

Elexacaftor–tezacaftor–ivacaftor enhances first-phase insulin secretion and improves glucose control in cystic fibrosis

Endocrine Connections
Objective: Cystic fibrosis (CF) is a congenital condition caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. CF-related diabetes (CFRD) is a common comorbidity among people with CF (pwCF) and is associated with increased ...
Anna Edlund, Ulrika Lindberg, Katarina Fagher, Lisa I Påhlman   +3 more
doaj   +1 more source

Role of CFTR in Epithelial to Mesenchymal Transition (EMT) by functional genomics

, 2021
Mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein cause Cystic Fibrosis (CF), the most common life-shortening monogenic condition in Caucasians.
Quaresma, Margarida C
core